| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2256 | 2015 |
| ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A CT Williamson, R Miller, HN Pemberton, SE Jones, J Campbell, A Konde, ... Nature communications 7 (1), 13837, 2016 | 318 | 2016 |
| ATM deficiency sensitizes mantle cell lymphoma cells to poly (ADP-ribose) polymerase-1 inhibitors CT Williamson, H Muzik, AG Turhan, A Zamò, MJ O'Connor, DG Bebb, ... Molecular cancer therapeutics 9 (2), 347-357, 2010 | 207 | 2010 |
| Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors TA Yap, B O’Carrigan, MS Penney, JS Lim, JS Brown, ... Journal of Clinical Oncology 38 (27), 3195, 2020 | 182 | 2020 |
| Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53 CT Williamson, E Kubota, JD Hamill, A Klimowicz, R Ye, H Muzik, M Dean, ... EMBO molecular medicine 4 (6), 515-527, 2012 | 145 | 2012 |
| Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines E Kubota, CT Williamson, R Ye, A Elegbede, L Peterson, SP Lees-Miller, ... Cell cycle 13 (13), 2129-2137, 2014 | 143 | 2014 |
| Large-scale profiling of kinase dependencies in cancer cell lines J Campbell, CJ Ryan, R Brough, I Bajrami, HN Pemberton, IY Chong, ... Cell reports 14 (10), 2490-2501, 2016 | 118 | 2016 |
| Directing the use of DDR kinase inhibitors in cancer treatment I Brandsma, EDG Fleuren, CT Williamson, CJ Lord Expert opinion on investigational drugs 26 (12), 1341-1355, 2017 | 100 | 2017 |
| Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib RE Miller, R Brough, I Bajrami, CT Williamson, S McDade, J Campbell, ... Molecular cancer therapeutics 15 (7), 1472-1484, 2016 | 95 | 2016 |
| The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status M Kim, CT Williamson, J Prudhomme, DG Bebb, K Riabowol, PWK Lee, ... Oncogene 29 (27), 3990-3996, 2010 | 75 | 2010 |
| Modeling Therapy Resistance in BRCA1/2-Mutant Cancers A Dréan, CT Williamson, R Brough, I Brandsma, M Menon, A Konde, ... Molecular cancer therapeutics 16 (9), 2022-2034, 2017 | 69 | 2017 |
| ATR is a therapeutic target in synovial sarcoma SE Jones, EDG Fleuren, J Frankum, A Konde, CT Williamson, DB Krastev, ... Cancer research 77 (24), 7014-7026, 2017 | 52 | 2017 |
| DNA-dependent SUMO modification of PARP-1 N Zilio, CT Williamson, S Eustermann, R Shah, SC West, D Neuhaus, ... DNA repair 12 (9), 761-773, 2013 | 27 | 2013 |
| Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC LF Petersen, AC Klimowicz, S Otsuka, AA Elegbede, SK Petrillo, ... Oncotarget 8 (24), 38326, 2017 | 24 | 2017 |
| Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness H Holme, A Gulati, R Brough, EDG Fleuren, I Bajrami, J Campbell, ... Scientific reports 8 (1), 10614, 2018 | 17 | 2018 |
| Preclinical evaluation of a novel SHIP1 phosphatase activator for inhibition of PI3K signaling in malignant B cells EA Lemm, B Valle-Argos, LD Smith, J Richter, Y Gebreselassie, MJ Carter, ... Clinical Cancer Research 26 (7), 1700-1711, 2020 | 14 | 2020 |
| DNA Double Strand Break Repair: Mechanisms and Therapeutic Potential LM Williamson, CT Williamson, SP Lees-Miller The DNA Damage Response: Implications on Cancer Formation and Treatment, 157-177, 2009 | 4 | 2009 |
| Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer CJ Lord, C Williamson, S Jones US Patent App. 16/067,994, 2019 | 1 | 2019 |
| ATM DEFICIENCY IS ASSOCIATED WITH WORSE OUTCOME IN RESECTED NON-SMALL CELL LUNG CANCER G Bebb, AC Klimowicz, T Williamson, S Petrillo, J Fralick, S Otsuka, ... JOURNAL OF THORACIC ONCOLOGY 6 (6), S1108-S1109, 2011 | 1 | 2011 |
| Effect of inhibition of PARP-1 on mantle cell lymphoma cells with dysfunctional ATM C Williamson, DG Bebb, H Muzik, SP Lees-Miller Journal of Clinical Oncology 26 (15_suppl), 8584-8584, 2008 | 1 | 2008 |
Christopher LordProfessor of Cancer Genomics, Institute of Cancer Research, London, UKVerified email at icr.ac.uk
